Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. MoonLake Immunotherapeutics shares valued at $46,827,628 were sold by Chen Bihua on Sep 29 ’25. At $7.21 per share, Chen Bihua sold 6,494,151 shares. The insider’s holdings dropped to 2,000,000 shares worth approximately $14.92 million following the completion of this transaction.
Also, Chen Bihua sold 5,827 shares, netting a total of over 40,556 in proceeds. Following the sale of shares at $6.96 each, the insider now holds 1,994,173 shares.
Before that, Moukheibir Catherine had sold 23,500 shares from its account. In a trade valued at $1,146,565, the Director traded MoonLake Immunotherapeutics shares for $48.79 each. Upon closing the transaction, the insider’s holdings decreased to 23,500 shares, worth approximately $0.0.
As published in a research note from H.C. Wainwright on October 02, 2025, MoonLake Immunotherapeutics [MLTX] has been rated down from a Buy to a Neutral. Analysts at Goldman downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early October. As of September 30, 2025, Wolfe Research has decreased its “an Outperform” rating to a “an Underperform” for MLTX. Earlier on September 30, 2025, Citigroup downgraded its rating. Their new recommendation was “a Neutral” for MLTX stock which previously was a “a Buy”.
Analyzing MLTX Stock Performance
On last trading session, MoonLake Immunotherapeutics [NASDAQ: MLTX] rose 5.67% to $7.46. The stock’s lowest price that day was $6.56, but it reached a high of $7.46 in the same session. During the last five days, there has been a drop of approximately -86.77%. Over the course of the year, MoonLake Immunotherapeutics shares have dropped approximately -85.20%. Shares of the company reached a 52-week high of $62.75 on 09/26/25 and a 52-week low of $5.95 on 09/29/25.
Support And Resistance Levels for MoonLake Immunotherapeutics (MLTX)
According to the 24-hour chart, there is a support level at 6.86, which, if violated, would cause prices to drop to 6.26. In the upper region, resistance lies at 7.76. The next price resistance is at 8.06. RSI (Relative Strength Index) is 20.23 on the 14-day chart, showing oversold technical sentiment.
Is MoonLake Immunotherapeutics subject to short interest?
Stocks of MoonLake Immunotherapeutics saw a sharp steep in short interest on 2025-09-15 dropping by -0.42 million shares to 4.95 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 5.37 million shares. A decline of -8.43% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.9 of the overall float, the days-to-cover ratio (short ratio) decline to 7.9.
Which companies own the most shares of MoonLake Immunotherapeutics (MLTX)?
In terms of MoonLake Immunotherapeutics share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 41.64% from the previous closing price of $7.06. Analysts anticipate MoonLake Immunotherapeutics stock to reach 20 by 2025, with the lowest price target being 7. In spite of this, 6 analysts ranked MoonLake Immunotherapeutics stock as Buy at the end of 2025. On September 29, 2025, Stifel assigned a price target of “a Hold” to the stock and downgraded coverage with a $13.
